Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $47.0 million.

  • Vanda Pharmaceuticals' Change in Acquisitions & Divestments fell 5135.13% to $47.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $208.2 million, marking a year-over-year decrease of 4085.22%. This contributed to the annual value of $208.2 million for FY2025, which is 4085.22% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $47.0 million for Q4 2025, which was down 5135.13% from $35.6 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $350.4 million for Q1 2023, and its period low was $35.6 million during Q3 2025.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $85.1 million (2022), whereas its average is $95.3 million.
  • In the last 5 years, Vanda Pharmaceuticals' Change in Acquisitions & Divestments soared by 28899.81% in 2023 and then plummeted by 8273.35% in 2024.
  • Vanda Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $79.4 million in 2021, then increased by 0.74% to $80.0 million in 2022, then soared by 40.14% to $112.1 million in 2023, then decreased by 13.83% to $96.6 million in 2024, then crashed by 51.35% to $47.0 million in 2025.
  • Its last three reported values are $47.0 million in Q4 2025, $35.6 million for Q3 2025, and $38.0 million during Q2 2025.